Surface functionalizing of a lipid nanosystem to promote brain targeting: step-by-step design and physico-chemical characterization

References

• Wiley DT, Webster P, Aaron G, Davis MA. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci USA 2013;110:8662–8667
   PubMed Web of Science ®Google Scholar
• Cerletti A, Drewe J, Fricker G, et al. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 2000;8:435–446
   PubMed Web of Science ®Google Scholar
• Sandip BT, Mansoor MA. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3:219–232
   PubMedGoogle Scholar
• Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem 2013;18:238428
   Google Scholar
• Van Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. J Control Release 2011;150:30–36
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011;150:2–22
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan Horses. J Control Release 2007;122:345–348
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439–462
   PubMed Web of Science ®Google Scholar
• Martin FJ, Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. J Biol Chem 1982;257:286–288
   PubMed Web of Science ®Google Scholar
• Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 1990;132:25–35
   PubMed Web of Science ®Google Scholar
• Zuidam NJ, Vrueh R, Crommelin DJA. Characterization of liposomes. In: Torchilin VP, Weissig V, eds. Liposomes: a practical approach. 2nd ed. New York: Oxford University Press; 2011:31–78
   Google Scholar
• Duncan RJS, Weston PD, Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins and its use in the preparation of conjugates for immunoassay. Anal Biochem 1983;132:68–73
   PubMed Web of Science ®Google Scholar
• Shaner NC, Campbell RE, Steinbach PA, et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004;22:1567–1572
   PubMed Web of Science ®Google Scholar
• Chaudhury A, Dasb S, Leea RFS, et al. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration. Int J Pharm 2011;430:167–175
   Web of Science ®Google Scholar
• Hansen CB, Kao GY, Moase EH, et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochem Biophys Acta 1995;1239:133–144
   PubMed Web of Science ®Google Scholar
• Keishi S, Hiroshi U. Detection of nanosized ordered domains in DOPC/DPPC and DOPC/Ch binary lipid mixture systems of large unilamellar vesicles using a TEMPO Quenching Method. Langmuir 2013;29:4830–4838
   PubMed Web of Science ®Google Scholar
• Jones MN, Hudson MJ. The targeting of immunoliposomes to tumour cells (A431) and the effects of encapsulated methotrexate. Biochem Biophys Acta 1993;1152:231–242
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRX 2005;2:99–107
   PubMedGoogle Scholar
• Woodle MC. Sterically stabilized liposome therapeutics. Adv Drugs Deliv Rev 1995;16:249–265
   Web of Science ®Google Scholar
• Schneider T, Sachse A, Leike J, et al. Surface modification of continuously extruded contrast-carrying liposomes: effect on their physical properties. Int J Pharm 1996;132:9–21
   Web of Science ®Google Scholar
• Persson D, Thorén PEG, Esbjfröner EK, et al. Membrane binding and translocation of cell-penetrating peptides. Biochem Biophys Acta 2004;1665:142–155
   PubMed Web of Science ®Google Scholar
• López-Pinto JM, González-Rodríguez ML, Rabasco AM. Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes. Int J Pharm 2005;298:1–12
   PubMed Web of Science ®Google Scholar
• Miyawaki A, Llopis J, Heim R, et al. Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin. Nature 1997;388:882–887
   PubMed Web of Science ®Google Scholar
• Varga Z, Mihály J, Berényi SZ, Bóta A. Structural characterization of the poly(ethylene glycol) layer of sterically stabilized liposomes by means of FTIR spectroscopy. Eur Polym J 2013;49:2415–2421
   Web of Science ®Google Scholar
• Eksperiandova LP, Fedorov OI, Stepanenko NA. Estimation of metrological characteristics of the element analyzer EuroVectorEA-3000 and its potential in the single-reactor CHNS mode. Microchem J 2011;99:235–238
   Web of Science ®Google Scholar
• Ayen WY, Kumar N. A systematic study on lyophilization process of polymersomes for long-term storage using doxorubicin-loaded (PEG) 3-PLA nanopolymersomes. Eur J Pharm Sci 2012;46:405–414
   PubMed Web of Science ®Google Scholar
• Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, et al. The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 2005;291:79–86
   PubMed Web of Science ®Google Scholar
• Visser CC, Stevanovic S, Voorwinden LH, et al. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Pharm Sci 2005;25:299–305
   Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009;71:251–256
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Molecular Trojan Horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006;6:494–500
   PubMed Web of Science ®Google Scholar
• Boado RJ, Pardridge WM. The Troyan Horse liposome technology for nonviral gene transfer across the blood-brain barrier. J Drug Deliv 2011;2011:296151 doi:10.1155/2011/296151
   PubMedGoogle Scholar
• Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol 2007;373:507–528
   Google Scholar
• Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 2007;24:1772–1787
   PubMed Web of Science ®Google Scholar
• Zhang Y, Boado RJ, Pardridge WM. Marked enhancement in gene expression by targeting the human insulin receptor. J Gene Med 2003;5:157–163
   PubMed Web of Science ®Google Scholar
• Xia CF, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007;12:2309–2316
   Web of Science ®Google Scholar
• Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomed 213;8:951–960
   PubMed Web of Science ®Google Scholar
• Cózar-Bernal MJ, Rabasco AM, Villasmil S, González-Rodríguez ML. Novedades en inmunoliposomas funcionalizados como sistemas vectores de péptidos a nivel cerebral. Rev Ind Farm 2012;171:51–62
   Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000;2:45–59
   PubMed Web of Science ®Google Scholar
• Misra A, Ganesh S, Shahiwalla A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003;6:252–273
   PubMed Web of Science ®Google Scholar